Friday, September 12, 2008 6:53:51 PM
Predictions:
Hello All!
Please no one take offense to my opinion, I am just speaking my mind. I don't wish to enter into any verbal sparing. For those of you who are dedicated to this company I think you will find some solace in my view.
I have been in SYBD/OXBO since day one. My position is quite sizeable, however I must admit that I have sold off as I forecasted this very situation.
As far as the 'topical'... Many have said that this is an attempt to hedge the fear over rejection of FDA approval. On the contrary this is a discovery of another revenue source that is an attempt to hedge against the weakening market. In such a volatile time, election/war/crap market, often small speculative co's such as OXBO are the first to get overlooked and sold off. The company is merely trying to anchor it's value with some earnings. I wouldn't over react or read too much into it. I have heard that Nov. 2009 is a shelf date, that will be great.
Now, as far as the main product, which we all can agree I assume, tests are looking really good. However, you have to understand there are many stock price variables...
Novice Investors
Scared Investors
Under Funded Investors
All these investors and their reactions to... economy, personal finances, lack of understanding of the FDA process, lack of understanding of the market (blood products) etc...
I know you old timers were ready for this very behavior and maybe some stayed true and maybe some sold knowing they could get back in.
Sadly or Happily depending on how you look at it and will 'play it', with my analysis I don't think we are at the bottom.
This is what I would say to expect.
I think we will stabilize for the next two weeks at a range of .44-.51 with it going as high as .56. Following that period we will have a slow burn decline to the neighborhood of .32-.38.
As the FDA meet nears all will go quiet and the stock will drop as low as .24
FDA will approve the protocol and all will progress, however don't expect a huge jump. People won't have the money, nor the stomach to jump back in.
Slowly it will claw it's way up to .50 by Jan and then after that I think we can see a crack of $2 by mid to late 2009.
Just my two cents... Please don't jump down my throat but I would love to hear some intellectual discourse on the subject.
Hello All!
Please no one take offense to my opinion, I am just speaking my mind. I don't wish to enter into any verbal sparing. For those of you who are dedicated to this company I think you will find some solace in my view.
I have been in SYBD/OXBO since day one. My position is quite sizeable, however I must admit that I have sold off as I forecasted this very situation.
As far as the 'topical'... Many have said that this is an attempt to hedge the fear over rejection of FDA approval. On the contrary this is a discovery of another revenue source that is an attempt to hedge against the weakening market. In such a volatile time, election/war/crap market, often small speculative co's such as OXBO are the first to get overlooked and sold off. The company is merely trying to anchor it's value with some earnings. I wouldn't over react or read too much into it. I have heard that Nov. 2009 is a shelf date, that will be great.
Now, as far as the main product, which we all can agree I assume, tests are looking really good. However, you have to understand there are many stock price variables...
Novice Investors
Scared Investors
Under Funded Investors
All these investors and their reactions to... economy, personal finances, lack of understanding of the FDA process, lack of understanding of the market (blood products) etc...
I know you old timers were ready for this very behavior and maybe some stayed true and maybe some sold knowing they could get back in.
Sadly or Happily depending on how you look at it and will 'play it', with my analysis I don't think we are at the bottom.
This is what I would say to expect.
I think we will stabilize for the next two weeks at a range of .44-.51 with it going as high as .56. Following that period we will have a slow burn decline to the neighborhood of .32-.38.
As the FDA meet nears all will go quiet and the stock will drop as low as .24
FDA will approve the protocol and all will progress, however don't expect a huge jump. People won't have the money, nor the stomach to jump back in.
Slowly it will claw it's way up to .50 by Jan and then after that I think we can see a crack of $2 by mid to late 2009.
Just my two cents... Please don't jump down my throat but I would love to hear some intellectual discourse on the subject.
Recent TENX News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/20/2026 09:05:19 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 10:55:54 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 09:26:02 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:31:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 09:08:07 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:56:40 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/12/2026 09:01:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 08:06:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 12:00:07 PM
- Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/12/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/08/2026 10:19:02 PM
- Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/08/2026 08:05:00 PM
- Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer • GlobeNewswire Inc. • 05/04/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 12:19:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/22/2026 12:17:37 PM
